PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?

PHASE3CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

August 4, 2023

Study Completion Date

August 4, 2023

Conditions
Breast CancerNon Hodgkin Lymphoma
Interventions
DRUG

Enalapril

Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion

Trial Locations (1)

TS4 3BW

South Tees Hospitals NHS FT, Middlesbrough

All Listed Sponsors
collaborator

Newcastle University

OTHER

collaborator

University of Durham

OTHER

collaborator

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER

lead

South Tees Hospitals NHS Foundation Trust

OTHER

NCT03265574 - PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? | Biotech Hunter | Biotech Hunter